Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.97M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $301.8K in total
- 4
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 33
- 13F valueReported value at the end of Q2 2026
- $8.97M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GRCE, Q2 2026
No superinvestor reported holding GRCE at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Grace Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)6:19 PM ET | Sep 21-23 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.1K | $2.10 | +$31.7K | +0.5%2.86M after | 2 lots |
| Sep 10, 2026 (view filing)4:05 PM ET | Sep 8-9 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.2K | $2.09 | +$31.9K | +0.6%2.78M after | 2 lots |
| Sep 10, 2026 (view filing)7:30 AM ET | Sep 9 | 1 day | Kohli PrashantChief Executive Officer | PPurchase | +100.0K | $2.14 | +$214.0K | +468.2%121.4K after | |
| Aug 19, 2026 (view filing)7:44 AM ET | Aug 14 | 5 daysLate | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +11.6K | $2.09 | +$24.2K | +0.4%2.76M after | |
| Sep 27, 2023 (view filing)7:46 PM ET | Sep 25 | 2 days | Kavuru VimalDirector, 10% Owner | PPurchase | +676.4K | $1.85 | +$1.25M | +132.2%1.19M after | |
| Sep 27, 2023 (view filing)7:46 PM ET | Sep 25 | 2 days | Kavuru VimalDirector, 10% Owner | PPurchase | +422.7K | $0.125 | +$52.8K | –422.7K after | Derivative |
| Sep 5, 2023 (view filing) | Aug 31 | 5 days | Olds DonaldDirector | PPurchase | +381 | $2.05 | +$781.05 | New position381 after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Grace Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cerity Partners LLC | 849,055 | $1.93M | 0.00% | 00.0% | Unchanged |
| Eversept Partners, LP | 772,900 | $1.75M | 0.10% | +16,300+2.2% | Added |
| Bank of America Corp | 494,698 | $1.12M | 0.00% | −250.0% | Reduced |
| Vanguard Capital Management LLC | 411,714 | $934.6K | 0.00% | +10,058+2.5% | Added |
| Citadel Advisors LLC | 349,740 | $793.9K | 0.00% | +250,998+254.2% | Added |
| Cantor Fitzgerald, L. P. | 200,000 | $454.0K | 0.00% | +200,000 | New |
| Maven Securities LTD | 200,000 | $454.0K | 0.03% | +200,000 | New |
| Birchview Capital, LP | 120,000 | $272.4K | 0.13% | +70,000+140.0% | Added |
| Two Sigma Investments, LP | 96,890 | $219.9K | 0.00% | +96,890 | New |
| Jane Street Group, LLC | 89,442 | $203.0K | 0.00% | −77,655−46.5% | Reduced |